Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29120365 | 0.84 | MAPT (0.67) | MAPTALDH1A1NPSR1TDP1KDM4E | |
| SCHEMBL31522203 | 0.84 | SLC34A1 (0.47) | SLC34A1MAPTALDH1A1NPSR1TDP1 | |
| SCHEMBL14353427 | 0.83 | CYP1A2 (0.62) | SLC34A1MAPTALDH1A1L3MBTL1LMNA | |
| SCHEMBL18865774 | 0.83 | SLC34A1 (0.43) | SLC34A1MAPTALDH1A1NPSR1TDP1 | |
| SCHEMBL15362173 | 0.82 | MAPT (0.57) | SLC34A1MAPTALDH1A1NPSR1TDP1 | |
| SCHEMBL18622981 | 0.81 | KDM4E (0.53) | SLC34A1MAPTALDH1A1NPSR1TDP1 | |
| SCHEMBL18865766 | 0.80 | FLT3 (0.43) | SLC34A1MAPTALDH1A1NPSR1TDP1 | |
| SCHEMBL18865866 | 0.79 | PDPK1 (0.53) | SLC34A1MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL18865550 | 0.79 | SLC34A1 (0.44) | SLC34A1MAPTALDH1A1NPSR1TDP1 | |
| SCHEMBL31254585 | 0.79 | PTGS2 (0.54) | SLC34A1MAPTALDH1A1NPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| CN-109071520-B | Microbicidal oxadiazole derivatives | 先正达参股股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114292234-A | Preparation method of pyrazole derivative | 南方海洋科学与工程广东省实验室(湛江) | 2022-04-08 | — | — | CN | disclosed |
| EP-3433252-B1 | MICROBICIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| US-11083196-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-08-10 | — | — | US | disclosed |
| EP-3433252-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162868-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-09-28 | — | — | WO | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2233469-B1 | Method for coupling halogen-substituted aromatic substances with trialkylsilyl-substituted heteroatom-containing organic compounds | ZYLUM BETEILIGUNGSGMBH & CO PATENTE II KG (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-2408741-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | Zylum Beteiligungsgesellschaft mbH & Co. Patente II KG (DE) | 2012-01-25 | — | — | EP | disclosed |
| EP-2233469-A1 | Method for coupling halogen-substituted aromatic substances with trialkylsilyl-substituted heteroatom-containing organic compounds | Zylum Beteiligungsgesellschaft mbH & Co. Patente II KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010106078-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | SLC34A1 1375/4885MAPT 3590/4885ALDH1A1 1105/4885 |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | TYR, ALK, TTL | SLC34A1 3399/4885MAPT 1726/4885ALDH1A1 2734/4885 |
| US-11083196-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | SLC34A1 2070/4885MAPT 4790/4885ALDH1A1 476/4885 |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | SLC34A1 3821/4885MAPT 3373/4885ALDH1A1 633/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | SLC34A1 3821/4885MAPT 3373/4885ALDH1A1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.